These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17941368)

  • 1. Rebound of psoriasis after efalizumab discontinuation, despite being on high-dose cyclosporine.
    Maskatia ZK; Koo J
    J Drugs Dermatol; 2007 Sep; 6(9):941-4. PubMed ID: 17941368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
    Menter A; Hamilton TK; Toth DP; Leung HM; Wetherill G; Hennessey B; Garovoy M; Kwon P; Pariser DM;
    Int J Dermatol; 2007 Jun; 46(6):637-48. PubMed ID: 17550570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rebound of psoriasis during treatment with efalizumab.
    Golda N; Benham SM; Koo J
    J Drugs Dermatol; 2006 Jan; 5(1):63-5. PubMed ID: 16468294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with moderate to severe plaque psoriasis: one year after the European Medicines Agency recommendation of efalizumab suspension.
    Talamonti M; Teoli M; Botti E; Spallone G; Chimenti S; Costanzo A
    Dermatology; 2011; 222(3):250-5. PubMed ID: 21494026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence.
    Papp KA; Toth D; Rosoph L
    BMC Dermatol; 2006 Oct; 6():9. PubMed ID: 17067371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab- and methotrexate-resistant rebound of psoriasis after discontinuation of efalizumab (Raptiva).
    Thielen AM; Barde C; Saurat JH
    Br J Dermatol; 2006 Oct; 155(4):846-7. PubMed ID: 16965444
    [No Abstract]   [Full Text] [Related]  

  • 7. Efalizumab rebound response to a sequential therapy of infliximab followed by efalizumab.
    Brunasso AM; Delfino C; Massone C
    Dermatology; 2009; 218(1):73-4. PubMed ID: 18841002
    [No Abstract]   [Full Text] [Related]  

  • 8. Efalizumab discontinuation: a practical strategy.
    Pugashetti R; Koo J
    J Dermatolog Treat; 2009; 20(3):132-6. PubMed ID: 19459081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple side effects of Efalizumab in a Saudi female with chronic persistent psoriasis followed by severe rebound after Efalizumab discontinuation.
    Bukhari IA
    Saudi Med J; 2007 Nov; 28(11):1745-7. PubMed ID: 17965804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy.
    Costanzo A; Talamonti M; Spallone G; Botti E; Chimenti MS; Papoutsaki M; Chimenti S
    Dermatology; 2009; 218(2):146-50. PubMed ID: 18971577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efalizumab].
    Descamps V
    Ann Dermatol Venereol; 2006; 133(8-9 Pt 1):666-78. PubMed ID: 17053736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of inverse psoriasis with efalizumab.
    George D; Rosen T
    J Drugs Dermatol; 2009 Jan; 8(1):74-6. PubMed ID: 19180901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapse, rebound, and psoriasis adverse events: an advisory group report.
    Carey W; Glazer S; Gottlieb AB; Lebwohl M; Leonardi C; Menter A; Papp K; Rundle AC; Toth D
    J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S171-81. PubMed ID: 16488339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective management of psoriasis symptom worsening during efalizumab therapy without discontinuing treatment: a case study.
    Gisondi P; Giglio MD; Girolomoni G
    J Dermatolog Treat; 2006; 17(3):172-5. PubMed ID: 16854760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical outcomes in patients with psoriasis following discontinuation of efalizumab due to suspension of marketing authorization].
    Baniandrés O; Pulido A; Silvente C; Suárez R; Lázaro P
    Actas Dermosifiliogr; 2010 Jun; 101(5):421-7. PubMed ID: 20525485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efalizumab in the treatment of psoriasis.
    Leonardi CL
    Dermatol Ther; 2004; 17(5):393-400. PubMed ID: 15379774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disseminated cryptococcal infection in a patient with severe psoriasis treated with efalizumab, methotrexate and ciclosporin.
    Tuxen AJ; Yong MK; Street AC; Dolianitis C
    Br J Dermatol; 2007 Nov; 157(5):1067-8. PubMed ID: 17854358
    [No Abstract]   [Full Text] [Related]  

  • 18. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.
    Leonardi CL; Papp KA; Gordon KB; Menter A; Feldman SR; Caro I; Walicke PA; Compton PG; Gottlieb AB;
    J Am Acad Dermatol; 2005 Mar; 52(3 Pt 1):425-33. PubMed ID: 15761420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythroderma in two patients with psoriasis upon discontinuation of efalizumab treatment.
    Kop EN; Körver JE; Van Ruysevelt D; De Jong EM; Van der Valk PG; Van de Kerkhof PC
    J Dermatolog Treat; 2009; 20(1):67-9. PubMed ID: 18651300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palmoplantar pustular psoriasis: successful therapy with efalizumab after non-response to infliximab.
    Wozel G; Vitez L
    Acta Derm Venereol; 2008; 88(2):169-70. PubMed ID: 18311451
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.